Chen Hongming 4
4 · Kala Pharmaceuticals, Inc. · Filed Mar 2, 2018
Insider Transaction Report
Form 4
Chen Hongming
Chief Scientific Officer10% Owner
Transactions
- Exercise/Conversion
Common Stock
2018-02-28$2.30/sh+4,000$9,200→ 50,080 total - Exercise/Conversion
Stock Option (right to buy)
2018-02-28−4,000→ 106,236 totalExercise: $2.30Exp: 2024-10-02→ Common Stock (4,000 underlying) - Exercise/Conversion
Common Stock
2018-02-28$2.24/sh+5,769$12,923→ 55,849 total - Exercise/Conversion
Stock Option (right to buy)
2018-02-28−5,769→ 0 totalExercise: $2.24Exp: 2023-09-27→ Common Stock (5,769 underlying)
Footnotes (2)
- [F1]This option was granted on October 2, 2014 and vests over four years, with 2.0833% of the shares underlying the option vested on August 21, 2014 and an additional 2.0833% of the shares vesting at the end of each successive one-month period thereafter.
- [F2]The option with respect to these shares is fully vested.